porfimer 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
polymers 4021 87806-31-3

Description:

MoleculeDescription

Synonyms:

  • porfimer sodium
  • photofrin
  • porfimer
The purified component of HEMATOPORPHYRIN DERIVATIVE, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (HEMATOPORPHYRIN PHOTORADIATION); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of PHOTODYNAMIC THERAPY in the United States.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 27, 1995 FDA CONCORDIA LABS INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XD01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Sensitizers used in photodynamic/radiation therapy
FDA PE N0000009801 Photosensitizing Activity
FDA MoA N0000010217 Photoabsorption
FDA EPC N0000175984 Photoactivated Radical Generator
CHEBI has role CHEBI:22587 antiviral agents
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:47868 photosensitising agent
CHEBI has role CHEBI:50177 dermatologic agent
MeSH PA D000970 Antineoplastic Agents
MeSH PA D003879 Dermatologic Agents
MeSH PA D017319 Photosensitizing Agents
MeSH PA D011838 Radiation-Sensitizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908
Malignant tumor of esophagus indication 363402007
Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia indication
High Grade Dysplasia associated with Barrett's Esophagus indication
Esophageal varices contraindication 28670008
Ulcer of esophagus contraindication 30811009
Stricture of esophagus contraindication 63305008
Kidney disease contraindication 90708001 DOID:557
Tracheoesophageal fistula contraindication 95435007
Bronchoesophageal fistula contraindication 235641005
Disease of liver contraindication 235856003 DOID:409
Thromboembolic disorder contraindication 371039008
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004
Bronchial Erosion due to Malignant Esophagus Neoplasm contraindication
Tracheal Erosion due to Malignant Esophagus Neoplasm contraindication
Arterial Erosion by Tumor Growth contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4024058 VUID
N0000022063 NUI
D03327 KEGG_DRUG
4024058 VANDF
4039127 VANDF
C0058031 UMLSCUI
CHEBI:60773 CHEBI
CHEMBL1201481 ChEMBL_ID
CHEMBL2105866 ChEMBL_ID
M15H03K69B UNII
135577896 PUBCHEM_CID
DB00707 DRUGBANK_ID
225244 RXNORM
11252 MMSL
5320 MMSL
d03872 MMSL
006198 NDDF
006199 NDDF
108816003 SNOMEDCT_US
372545008 SNOMEDCT_US
386921007 SNOMEDCT_US
D017323 MESH_DESCRIPTOR_UI
6670 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Photofrin HUMAN PRESCRIPTION DRUG LABEL 1 76128-155 INJECTION, POWDER, FOR SOLUTION 75 mg INTRAVENOUS NDA 20 sections